0.3468

1.79% 0.0061

Soligenix Inc (SNGX)

Overview News Price History Financials Discussions Forecast Stock Split

Soligenix Inc stock is traded at $0.3468, with a volume of 136.54K. It is up +1.79% in the last 24 hours and down -3.69% over the past month. Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).

Previous Close:

$0.3407

Open:

$0.344

24h Volume:

136.54K

Relative Volume:

1.07

Market Cap:

$7.55M

Revenue:

$200.00K

Net Income/Loss:

$-10.95M

P/E Ratio:

-0.1757

EPS:

-1.9738

Net Cash Flow:

$-10.78M

1W Performance:

+0.06%

1M Performance:

-3.69%

6M Performance:

-69.84%

1Y Performance:

-78.05%

1-Day Range:

$0.3414

$0.35

1-Week Range:

$0.3248

$0.37

52-Week Range:

$0.28

$1.76

Soligenix Inc Stock (SNGX) Company Profile

Name

Soligenix Inc

Sector

Healthcare (1051)

Industry

Biotechnology (593)

Phone

609-538-8200

Address

29 EMMONS DRIVE, PRINCETON

Employee

Twitter

@Soligenix_Inc

Next Earnings Date

2026-11-06

Latest SEC Filings

SNGX's Discussions on Twitter

Compare SNGX vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SNGX Soligenix Inc	0.3468	7.55M	200.00K	-10.95M	-10.78M	-1.9738
VRTX Vertex Pharmaceuticals Inc	508.89	128.98B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	238.19	95.10B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	800.60	82.43B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.78	53.57B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	372.06	42.09B	5.76B	514.49M	1.10B	4.4813

Soligenix Inc Stock (SNGX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-28-20	Downgrade	Dawson James	Buy → Neutral
Jan-31-18	Downgrade	H.C. Wainwright	Buy → Neutral
Aug-14-17	Reiterated	Maxim Group	Buy
Jul-17-17	Initiated	H.C. Wainwright	Buy

Soligenix Inc Stock (SNGX) Latest News

Oct 14, 2026

Form 4 Soligenix Inc: Christopher J. Schaber (Director, CHAIRMAN, CEO AND PRESIDENT) For: 12 October - Investing.com Canada

Oct 14, 2026

Oct 13, 2026

For no payment, director Robert J. Rubin surrendered options on 632 Soligenix (SNGX) shares. - Stock Titan

Oct 13, 2026

Diane L. Parks surrenders options on 566 Soligenix (SNGX) shares for no payment. - Stock Titan

Oct 13, 2026

Options for 632 shares are surrendered to Soligenix (SNGX) for cancellation without payment. - Stock Titan

Oct 13, 2026

Options for 914 shares return to Soligenix (SNGX) for cancellation without payment. - Stock Titan

Oct 13, 2026

Sep 22, 2026

Soligenix Shareholders Approve Governance and Capital Changes - The Globe and Mail

Sep 22, 2026

Sep 18, 2026